Analyst Price Target is $4.10
▲ +163.67% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Ginkgo Bioworks in the last 3 months. The average price target is $4.10, with a high forecast of $6.00 and a low forecast of $1.25. The average price target represents a 163.67% upside from the last price of $1.56.
Current Consensus is
The current consensus among 6 contributing investment analysts is to hold stock in Ginkgo Bioworks. This rating has held steady since February 2022, when it changed from a Buy consensus rating.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.